Primary Ciliary Dyskinesia (PCD) Global Market Report 2025
상품코드:1760700
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
원발성 섬모 이상운동증(PCD) 시장 규모는 향후 몇 년 동안 강력한 성장세를 보이며 2029년까지 6.8%의 CAGR(연평균 성장률)로 6억 5,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 희귀 호흡기질환에 대한 인식 증가, 유전자 검사의 가용성 향상, 만성 호흡기 감염 사례 증가, 상환 정책 개선, 전문 진단 센터의 확대 등에 기인할 것으로 보입니다. 예측 기간의 주요 동향으로는 유전자 염기서열 분석 기술의 발전, 비침습적 진단 도구의 개발, 연구개발 협력의 증가, 기도 확보 장치의 혁신, 영상 진단에 인공지능의 통합 등을 꼽을 수 있습니다.
유전자 치료에 대한 수요 증가는 원발성 섬모 이상운동증(PCD) 시장 확대를 가속화할 것으로 예상됩니다. 유전자 치료는 환자의 세포 내 결함 유전자를 수정하거나 대체하여 질병을 치료하거나 예방하는 것입니다. 유전자 치료의 수요가 급증하는 배경에는 유전자 연구의 눈부신 발전으로 유전자 장애를 분자 수준에서 표적으로 교정하고, 보다 정밀한 치료가 가능해져 환자의 예후가 개선된 것이 있습니다. 특히 원발성 섬모 이상운동증(PCD)의 경우, 호흡기의 섬모 기능 장애를 일으키는 유전자 돌연변이를 교정하는 유전자 치료법이 개발되고 있습니다. 이 치료법은 건강한 유전자를 도입하여 정상적인 섬모 운동을 회복하고, 점액 제거를 강화하며, 호흡기 감염을 감소시키는 것을 목표로 하고 있습니다. 예를 들어, 2023년 7월 미국의 전문 회원 조직인 미국 유전자세포 치료학회(ASGCT)는 2023년 2분기까지 임상 2상 시험 중인 유전자 치료 프로그램 수가 260개에 달해 1분기 대비 5% 증가했다고 보고했습니다. 이러한 유전자 치료에 대한 관심 증가가 원발성 섬모 이상운동증 시장의 성장을 견인하고 있습니다.
원발성 섬모 이상운동증(PCD) 시장의 주요 업체들은 증상 관리를 개선하고 환자의 삶의 질을 향상시키기 위해 임상시험 중인 mRNA 기반 치료제와 같은 혁신적인 치료법 개발에 주력하고 있습니다. 질병 치료 및 예방에 도움이 되는 단백질 생산을 세포에 지시합니다. 이 최첨단 접근법은 분자 수준에서 병태생리를 표적화하여 맞춤형 의료로 이어집니다. 예를 들어, 2024년 6월 미국 생명공학 기업 ReCode Therapeutics, Inc.는 임상시험 중인 흡입형 mRNA 치료제인 RCT1100을 출시했습니다. 이 치료법은 미국 식품의약국(FDA)으로부터 원발성 섬모 이상운동증 치료제로 희귀의약품 지정을 받았으며, RCT1100은 DNAI1 mRNA를 기도 세포에 직접 전달하여 섬모 기능을 회복시키는 것을 목표로 하며, 질환에 대한 질병 변형 치료나 치료법이 존재하지 않아 미국 내 약 4만5,000명으로 추산되는 환자들에게 중요한 미충족 수요를 충족시킬 수 있는 치료제입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 원발성 섬모 이상운동증(PCD) PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 원발성 섬모 이상운동증(PCD) 시장 : 성장률 분석
세계의 원발성 섬모 이상운동증(PCD) 시장 실적 : 규모와 성장, 2019-2024
세계의 원발성 섬모 이상운동증(PCD) 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 원발성 섬모 이상운동증(PCD) 전체 시장(TAM)
제6장 시장 세분화
세계의 원발성 섬모 이상운동증(PCD) 시장 : 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
항생제
기도 청결 요법
외과적 개입
기타 치료법
세계의 원발성 섬모 이상운동증(PCD) 시장 : 방법별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
유전자 검사
영상 기술
임상 평가
폐기능 검사
세계의 원발성 섬모 이상운동증(PCD) 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
직접 판매
온라인 약국
서드파티 판매업체
소매 약국
세계의 원발성 섬모 이상운동증(PCD) 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
전문 클리닉
진단 검사실
기타 최종사용자
세계의 원발성 섬모 이상운동증(PCD) 시장, 항생제, 유형별 하위 세분화 : 실적과 예측, 2019-2024, 2024-2029F, 2034F
매크로라이드
페니실린
세팔로스포린
플루오로퀴놀론
아미노글리코사이드
세계의 원발성 섬모 이상운동증(PCD) 시장, 기도 청결 요법, 유형별 하위 세분화 : 실적과 예측, 2019-2024, 2024-2029F, 2034F
흉부 물리치료
고주파 흉벽 진동(HFCWO)
호기양압(PEP) 요법
폐내 진동 환기(IPV)
진동성 호기양압(OPEP)
세계의 원발성 섬모 이상운동증(PCD) 시장, 외과적 개입, 유형별 하위 세분화 : 실적과 예측, 2019-2024, 2024-2029F, 2034F
부비동 수술
고실 튜브 배치
폐이식
세계의 원발성 섬모 이상운동증(PCD) 시장, 기타 치료법, 유형별 하위 세분화 : 실적과 예측, 2019-2024, 2024-2029F, 2034F
점액용해제
면역조절 요법
유전자 치료
줄기세포 치료
제7장 지역별·국가별 분석
세계의 원발성 섬모 이상운동증(PCD) 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 원발성 섬모 이상운동증(PCD) 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
원발성 섬모 이상운동증(PCD) 시장 : 경쟁 구도
원발성 섬모 이상운동증(PCD) 시장 : 기업 개요
Centogene N.V. Overview, Products and Services, Strategy and Financial Analysis
Nationwide Children's Hospital Overview, Products and Services, Strategy and Financial Analysis
Revvity Inc. Overview, Products and Services, Strategy and Financial Analysis
Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis
Children's Healthcare of Atlanta Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Exact Sciences Corp.
University Hospital Southampton
UT Health East Texas
Guy's and St Thomas'NHS Foundation Trust
National Jewish Health
Vanderbilt University Medical Center
UNC School of Medicine
Stanford Medicine
Mayo Foundation for Medical Education and Research
DNA Labs India Pvt. Ltd.
Parion Sciences Inc.
ReCode Therapeutics Inc.
University Hospital Munster
UAB Health System
PCD Foundation
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
원발성 섬모 이상운동증(PCD) 시장 2029 : 새로운 기회를 제공하는 국가
원발성 섬모 이상운동증(PCD) 시장 2029 : 새로운 기회를 제공하는 부문
원발성 섬모 이상운동증(PCD) 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Primary ciliary dyskinesia (PCD) is a rare inherited disorder that affects the normal function and structure of cilia, which are microscopic, hair-like structures found in the airways, ears, and reproductive tract. Understanding and diagnosing PCD is essential for managing symptoms early and improving quality of life through targeted therapies.
The main types of treatment for primary ciliary dyskinesia (PCD) include antibiotics, airway clearance therapies, surgical interventions, and other supportive therapies. Antibiotics help treat respiratory bacterial infections, prevent lung damage, and maintain airway health. PCD is diagnosed through various methods, such as genetic testing, imaging techniques, clinical evaluation, and lung function tests. The treatments are distributed through multiple channels, including direct sales, online pharmacies, third-party distributors, and retail pharmacies. End-users of PCD treatments include hospitals, specialty clinics, diagnostic laboratories, and other healthcare providers.
The primary ciliary dyskinesia (PCD) market research report is one of a series of new reports from The Business Research Company that provides primary ciliary dyskinesia (PCD) market statistics, including the primary ciliary dyskinesia (PCD) industry global market size, regional shares, competitors with the primary ciliary dyskinesia (PCD) market share, detailed primary ciliary dyskinesia (PCD) market segments, market trends, opportunities, and any further data you may need to thrive in the primary ciliary dyskinesia (PCD) industry. This primary ciliary dyskinesia (PCD) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The primary ciliary dyskinesia market size has grown strongly in recent years. It will grow from $0.46 billion in 2024 to $0.50 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to increasing clinical confusion with other respiratory disorders, a greater reliance on symptomatic treatment, enhanced use of general respiratory therapies, expanded diagnosis based on exclusion methods, and a growing focus on cystic fibrosis, which often overshadowed primary ciliary dyskinesia.
The primary ciliary dyskinesia market size is expected to see strong growth in the next few years. It will grow to $0.65 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth during the forecast period can be attributed to growing awareness of rare respiratory diseases, improved availability of genetic testing, a rise in cases of chronic respiratory infections, better reimbursement policies, and the expansion of specialized diagnostic centers. Key trends in the forecast period include advancements in genetic sequencing technologies, the development of non-invasive diagnostic tools, increased research and development collaborations, innovations in airway clearance devices, and the integration of artificial intelligence in diagnostic imaging.
The growing demand for gene therapy is expected to accelerate the expansion of the primary ciliary dyskinesia (PCD) market. Gene therapy involves modifying or replacing faulty genes in a patient's cells to treat or prevent diseases. The demand for gene therapy has surged due to significant progress in genetic research, allowing for more precise treatments that target and correct genetic disorders at the molecular level, improving patient outcomes. In particular, gene therapy is being developed for Primary Ciliary Dyskinesia (PCD) to correct the genetic mutations responsible for defective cilia function in the respiratory system. This therapy aims to introduce healthy genes to restore normal ciliary movement, enhance mucus clearance, and reduce respiratory infections. For example, in July 2023, the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, reported that the number of gene therapy programs in Phase II clinical trials reached 260 by the second quarter of 2023, a 5% increase from the first quarter. This growing focus on gene therapy is driving the growth of the primary ciliary dyskinesia market.
Key players in the primary ciliary dyskinesia market are focusing on the development of innovative therapies, such as investigational mRNA-based treatments, to improve symptom management and enhance the quality of life for patients. mRNA-based therapeutics use messenger RNA (mRNA) to instruct cells to produce proteins that may treat or prevent diseases. This cutting-edge approach targets conditions at the molecular level, leading to personalized medicine. For instance, in June 2024, ReCode Therapeutics, Inc., a US-based biotechnology company, launched RCT1100, an investigational inhaled mRNA therapy. The therapy received orphan drug designation from the U.S. Food and Drug Administration (FDA) for treating primary ciliary dyskinesia. RCT1100 aims to restore ciliary function by delivering DNAI1 mRNA directly to airway cells, addressing a critical unmet need for the estimated 45,000 individuals affected by PCD in the U.S., as there are currently no disease-modifying treatments or cures for this condition.
In October 2024, PCD Research, a UK-based charitable organization focused on primary ciliary dyskinesia research, partnered with the Nucleic Acid Therapy Accelerator (NATA) to advance therapies for primary ciliary dyskinesia. The collaboration aims to co-fund a grant dedicated to developing innovative treatments for PCD, a rare genetic disorder that impairs respiratory function. The partnership seeks to support groundbreaking research that will improve treatment options and outcomes for individuals affected by this progressive and debilitating condition. NATA is a UK-based research initiative specializing in nucleic acid therapeutics.
Major players in the primary ciliary dyskinesia (pcd) market are Centogene N.V., Nationwide Children's Hospital, Revvity Inc., Quest Diagnostics Incorporated, Children's Healthcare of Atlanta, Exact Sciences Corp., University Hospital Southampton, UT Health East Texas, Guy's and St Thomas' NHS Foundation Trust, National Jewish Health, Vanderbilt University Medical Center, UNC School of Medicine, Stanford Medicine, Mayo Foundation for Medical Education and Research, DNA Labs India Pvt. Ltd., Parion Sciences Inc., ReCode Therapeutics Inc., University Hospital Munster, UAB Health System, PCD Foundation.
North America was the largest region in the primary ciliary dyskinesia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in primary ciliary dyskinesia (PCD) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the primary ciliary dyskinesia (PCD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary ciliary dyskinesia market consists of revenues earned by entities by providing services such as pulmonary rehabilitation, home healthcare services, and genetic counselling. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary ciliary dyskinesia market includes sales of immunofluorescence microscopy, transmission electron tomography, and whole-exome sequencing kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified.)
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Primary Ciliary Dyskinesia (PCD) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on primary ciliary dyskinesia (pcd) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for primary ciliary dyskinesia (pcd) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The primary ciliary dyskinesia (pcd) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment: Antibiotics; Airway Clearance Therapies; Surgical Interventions; Other Treatments
2) By Method: Genetic Testing; Imaging Techniques; Clinical Evaluation; Lung Function Tests
4) By Distribution Channel: Direct Sales; Online Pharmacies; Third-party Distributors; Retail Pharmacies
4) By End-User: Hospitals; Specialty Clinics; Diagnostic Laboratories; Other End-Users
Subsegments:
1) By Antibiotics: Macrolides; Penicillins; Cephalosporins; Fluoroquinolones; Aminoglycosides
3. Primary Ciliary Dyskinesia (PCD) Market Trends And Strategies
4. Primary Ciliary Dyskinesia (PCD) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Primary Ciliary Dyskinesia (PCD) Growth Analysis And Strategic Analysis Framework
5.1. Global Primary Ciliary Dyskinesia (PCD) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Primary Ciliary Dyskinesia (PCD) Market Growth Rate Analysis
5.4. Global Primary Ciliary Dyskinesia (PCD) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Primary Ciliary Dyskinesia (PCD) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Primary Ciliary Dyskinesia (PCD) Total Addressable Market (TAM)
6.1. Global Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antibiotics
Airway Clearance Therapies
Surgical Interventions
Other Treatments
6.2. Global Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Genetic Testing
Imaging Techniques
Clinical Evaluation
Lung Function Tests
6.3. Global Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Direct Sales
Online Pharmacies
Third-party Distributors
Retail Pharmacies
6.4. Global Primary Ciliary Dyskinesia (PCD) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Diagnostic Laboratories
Other End-Users
6.5. Global Primary Ciliary Dyskinesia (PCD) Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Macrolides
Penicillins
Cephalosporins
Fluoroquinolones
Aminoglycosides
6.6. Global Primary Ciliary Dyskinesia (PCD) Market, Sub-Segmentation Of Airway Clearance Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chest Physiotherapy
High-Frequency Chest Wall Oscillation (HFCWO)
Positive Expiratory Pressure (PEP) Therapy
Intrapulmonary Percussive Ventilation (IPV)
Oscillatory Positive Expiratory Pressure (OPEP)
6.7. Global Primary Ciliary Dyskinesia (PCD) Market, Sub-Segmentation Of Surgical Interventions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sinus Surgery
Tympanostomy Tube Placement
Lung Transplantation
6.8. Global Primary Ciliary Dyskinesia (PCD) Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Mucolytics
Immunomodulatory Therapies
Gene Therapy
Stem Cell Therapy
7. Primary Ciliary Dyskinesia (PCD) Market Regional And Country Analysis
7.1. Global Primary Ciliary Dyskinesia (PCD) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Primary Ciliary Dyskinesia (PCD) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Primary Ciliary Dyskinesia (PCD) Market
9.1. China Primary Ciliary Dyskinesia (PCD) Market Overview
9.2. China Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Primary Ciliary Dyskinesia (PCD) Market
10.1. India Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Primary Ciliary Dyskinesia (PCD) Market
11.1. Japan Primary Ciliary Dyskinesia (PCD) Market Overview
11.2. Japan Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Primary Ciliary Dyskinesia (PCD) Market
12.1. Australia Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Primary Ciliary Dyskinesia (PCD) Market
13.1. Indonesia Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Primary Ciliary Dyskinesia (PCD) Market
14.1. South Korea Primary Ciliary Dyskinesia (PCD) Market Overview
14.2. South Korea Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Primary Ciliary Dyskinesia (PCD) Market
15.1. Western Europe Primary Ciliary Dyskinesia (PCD) Market Overview
15.2. Western Europe Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Primary Ciliary Dyskinesia (PCD) Market
16.1. UK Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.1. Germany Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Primary Ciliary Dyskinesia (PCD) Market
18.1. France Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Primary Ciliary Dyskinesia (PCD) Market
19.1. Italy Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Primary Ciliary Dyskinesia (PCD) Market
20.1. Spain Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Primary Ciliary Dyskinesia (PCD) Market
21.1. Eastern Europe Primary Ciliary Dyskinesia (PCD) Market Overview
21.2. Eastern Europe Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Primary Ciliary Dyskinesia (PCD) Market
22.1. Russia Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Primary Ciliary Dyskinesia (PCD) Market
23.1. North America Primary Ciliary Dyskinesia (PCD) Market Overview
23.2. North America Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Primary Ciliary Dyskinesia (PCD) Market
24.1. USA Primary Ciliary Dyskinesia (PCD) Market Overview
24.2. USA Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Primary Ciliary Dyskinesia (PCD) Market
26.1. South America Primary Ciliary Dyskinesia (PCD) Market Overview
26.2. South America Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Primary Ciliary Dyskinesia (PCD) Market
27.1. Brazil Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Primary Ciliary Dyskinesia (PCD) Market
28.1. Middle East Primary Ciliary Dyskinesia (PCD) Market Overview
28.2. Middle East Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Primary Ciliary Dyskinesia (PCD) Market
29.1. Africa Primary Ciliary Dyskinesia (PCD) Market Overview
29.2. Africa Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Primary Ciliary Dyskinesia (PCD) Market Competitive Landscape And Company Profiles
